Low-dose (0.3 mg) synthetic conjugated estrogens a is effective for managing atrophic vaginitis

Maturitas

Volumn 47, Issue 1, 2004, Pages 47-54

  Marx, Phyllis ^a   Schade, George ^b   Wilbourn, Shelby ^c   Blank, Stephen ^d   Moyer, Dean L ^e   Nett, Robert ^f  

^a RADIANT RESEARCH   (United States)

^b Phoenix Center for Clinical Research   (United States)

^c Pharmacol Research Clinic Las Vegas   (United States)

^d Southeast Research Associates   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f San Antonio Center for Clinical Research   (United States)

Author keywords

Estrogens; Placebo; Urogenital atrophy

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO; PROGESTERONE;

ADULT; ARTICLE; ATROPHIC SKIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN TISSUE; LEUKORRHEA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; PH; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TABLET FORMULATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VAGINITIS;

EID: 0347628872     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00240-8     Document Type: Article

References (17)

1. Beers M.H., Berkow R. Gynecology and obstetrics. Beers M.H., Berkow R. The Merck manual of diagnosis and therapy. 17th ed. 1999;1942-1944 Merck Research Laboratories, Whitehouse Station, NJ.
2. Bachmann G.A. Urogenital aging: an old problem newly recognized. Maturitas. 22:(Suppl):1995;S1-S5.
3. Bachmann G.A., Nevadunsky N.S. Diagnosis and treatment of atrophic vaginitis. Am. Fam. Phys. 61:2000;3090-3096.
4. Greendale G.A., Judd H.L. The menopause: health implications and clinical management. L. Am. Geriatr. Soc. 41:1993;426-436.
5. Nilsson K., Risberg B., Heimer G. The vaginal epithelium in the postmenopause-cytology, histology, and pH as methods of assessment. Maturitas. 21:1995;51-56.
6. Semmens J.P., Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. J. Am. Med. Assoc. 248:1982;445-448.
7. Pandit L., Ouslander J.G. Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. 314:1997;228-231.
8. Rigg L.A. Estrogen replacement therapy for atrophic vaginitis. Int. J. Fertil. 31:1986;29-34.
9. Willhite L., O'Connell M.B. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 21:2001;464-480.
10. Cardozo L., Bachmann G., McClish D., Fonda D., Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet. Gynecol. 92:1998;722-727.
11. Osmers R., Volksen M., Schauer A. Vaginosonography for early detection of endometrial carcinoma? Lancet. 335:1990;1569-1571.
12. Geola F.L., Frumar A.M., Tataryn I.V., et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 51:1980;620-625.
13. Nilsson K.E., Heimer G.M. Ultra-low dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency - a placebo-controlled study. Menopause. 1:1994;191-197.
14. Nilsson K., Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - pharmacokinetic and pharmacodynamic study. Maturitas. 15:1992;121-127.
15. Mandel F.P., Geola F.L., Meldrun D.R., et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 57:1983;133-139.
16. Handa V.L., Bachus K.E., Johnston W.W., Robboy S.J., Hammond C.B. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet. Gynecol. 84:1994;215-218.
17. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil. Steril. 75:2001;1065-1079.